Drug Trial Radar · NCT07453602
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Arcutis Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Cohorts, and a Proof-of-Concept (POC) expansion cohort.
Conditions
- Atopic Dermatitis (AD)
- Eczema
Interventions
ARQ-234Biological
ARQ-234 subcutaneous injectable solution
PlaceboDrug
Placebo subcutaneous injectable solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants who experience an adverse event (AE) or serious adverse event (SAE)Time frame: From screening to the last follow up visit for each study part (Part A: 16 weeks, Part B: 30 weeks, Part C: 30 weeks)
- Percent change from Baseline in the Eczema Area and Severity Index (EASI) score, a validated measure of disease severity in atopic dermatitis.Time frame: From Baseline to Week 16
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 112
Miami, Florida · Recruiting
Clinical Site 110
Miami, Florida · Recruiting
Clinical Site 106
Plainfield, Indiana · Recruiting
Clinical Site 101
Fair Lawn, New Jersey · Recruiting
Clinical Site 102
College Station, Texas · Recruiting
Clinical Site 104
San Antonio, Texas · Recruiting
Clinical Site 109
South Jordan, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.